UBS AM
KALV

UBS AM’s KalVista Pharmaceuticals KALV Stock Holding History

UBS AM’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$699K Buy
34,743
+7,021
+25% +$113K ﹤0.01% 2460
2025
Q4 		$448K Buy
27,722
+14,122
+104% +$187K ﹤0.01% 2345
2025
Q3 		$166K Buy
+13,600
New +$188K ﹤0.01% 2228

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's KALV Position: Q1 2026 in Review

UBS AM increased its KalVista Pharmaceuticals (KALV) stake by 25% in Q1 2026, buying an estimated $113K and bringing the position to 34,743 shares worth $699K. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

UBS AM first reported a position in KALV in Q3 2025 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • UBS AM held 34,743 shares of KalVista Pharmaceuticals worth $699K as of Q1 2026.
  • UBS AM bought 7,021 KalVista Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • KalVista Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2460 holding.
  • UBS AM first reported a position in KalVista Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.